Secondary Outcomes
Three months after PPCI, secondary outcomes including in-hospital and out-of-hospital death due to cardiovascular diseases, re-infarction, cerebrovascular events, major bleeding, minor bleeding, TVR and TLR were investigated (Table 4). Investigations showed that the rate of re-infarction and performing TLR was significantly lower in the group that received Eptifibatide infusion, while there was no significant difference of death due to cardiovascular diseases, cerebrovascular events, major and minor bleeding and TVR between two groups.